KDR and neoplasm: Treatment with low doses of anti-VEGFR2 antibody resulted in a less immunosuppressive tumor microenvironment by the polarization of tumor-associated macrophages, and recruitment and activation of CD8+ T lymphocytes in a murine breast cancer model [63].